A New Frontier at the Intersection of Metabolism and Mental Health
Glucagon-like peptide-1 (GLP-1) receptor agonists have shifted from a metabolic innovation to a broader therapeutic phenomenon. Prescribing increased more than 300 percent between 2019 and 2022, driven by the U.S. obesity crisis and the growing adoption of semaglutide and related agents for weight management.1,2
As millions begin GLP-1 therapy, a second signal is emerging. Across real-world datasets, controlled trials, and preclinical models, GLP-1s appear to influence mood, reward processing, compulsivity, and cognitive control. These early findings suggest metabolic drugs may hold meaningful potential in neuropsychiatric care, but dedicated clinical trials are needed to determine whether these effects translate into actionable benefits or products.
Early Evidence Points to Promising Areas of Impact
The earliest clues come from people receiving GLP-1s for everyday metabolic reasons. In large real-world cohorts, adults starting semaglutide report fewer depressive symptoms than peers on other antidiabetic agents.3 Concomitantly, controlled trials in individuals with alcohol use disorder have found that exenatide or semaglutide can dampen alcohol cue reactivity and reduce craving intensity.4 And in preclinical research, animals treated with GLP-1 agonists cut their self-administration of alcohol, nicotine, and cocaine by up to half.5
These are compelling signals; however, none of the studies were designed to test GLP-1s as treatments for depression, addiction, or compulsive disorders. Purpose-built clinical trials are required to assess whether these effects can improve the course of neuropsychiatric illness.
The expanding scientific evidence on how GLP-1 agonists act in the brain is beginning to crystallize into five promising avenues of neuropsychiatric research:
1. Addiction and Reward Circuitry
GLP-1 agonists have demonstrated potential in reducing cravings and diminishing the rewarding effects of alcohol, nicotine, and stimulants. Real-world cohorts and controlled studies show decreased cue reactivity and lower craving intensity, while animal models exhibit up to a 50 percent reduction in drug self-administration. Taken together, these findings suggest GLP-1s engage dopamine-based reward circuits that underpin substance use disorders.6,7
2. Compulsive Behaviors
Emerging data suggest that GLP-1s may modulate neural circuits that govern reward, motivation, and behavioral inhibition. This has produced signals across conditions characterized by compulsivity, including binge eating and other repetitive, impulse-driven behaviors. By strengthening top-down regulatory networks, GLP-1s may help reduce urges and improve self-control. 8,9
3. Mood Disorders
Growing evidence links GLP-1 therapy to improvements in depressive symptoms among individuals treated for metabolic indications. Proposed mechanisms include modulation of serotonin, dopamine, and glutamate signaling, as well as improvements in inflammatory and metabolic parameters, and potential neuroprotective or neurogenic effects in regions such as the hippocampus. These signals are promising but require confirmation in trials designed for mood outcomes.10,11
4. Antipsychotic-Associated Weight Gain
GLP-1s are also being evaluated as a targeted strategy to mitigate weight gain induced by antipsychotic medications, a significant challenge in schizophrenia care. Existing interventions, such as metformin, often provide limited benefit. GLP-1s may offer a dual-benefit model: improving metabolic health while supporting psychiatric stability.12,13
5. Alzheimer’s Disease and Cognitive Decline
Clinical and observational data suggest GLP-1 agonists may confer neuroprotective benefits relevant to Alzheimer’s disease and other forms of dementia.14 Multiple Phase 2 trials (e.g., liraglutide, semaglutide) have demonstrated signals of slowed cognitive decline or preserved brain metabolism. At the same time, large real-world cohorts report lower dementia incidence among GLP-1 users compared with other antidiabetic therapies. These findings position GLP-1s as a potential disease-modifying strategy, pending results from ongoing and larger trials.
How GLP-1s Act in the Brain
A growing body of translational and clinical research suggests GLP-1 agonists may influence neuropsychiatric function through three major pathways:
1. Neurotransmitter Modulation
GLP-1s appear to influence dopamine, serotonin, and glutamate signaling, all of which play critical roles in reward, mood, impulse control, and decision-making.15
2. Neuroprotection and Neurogenesis
Preclinical studies demonstrate that GLP-1 agonists may promote neuronal survival, synaptic resilience, and neurogenesis within the hippocampus, leading to downstream effects on mood regulation and cognitive processing.16
3. Metabolic and Anti-Inflammatory Effects
Improvements in systemic inflammation, insulin sensitivity, and metabolic efficiency may influence neuroimmune pathways associated with depression, anhedonia, and cognitive slowing in patients with comorbid metabolic diseases.17
Safety Considerations and Known Unknowns
Although GLP-1s have a favorable safety profile in metabolic indications based on the available evidence, their long-term psychiatric use requires focused evaluation.18
- Depression and suicidality: Large observational studies and meta-analyses have not shown a significant increase in suicidality among GLP-1 users, but monitoring is essential.
- Neuropsychiatric side effects: Data remain limited in patients with severe mental illness or high baseline vulnerability.
- Drug interactions: No clinically meaningful interactions with SSRIs or other common psychiatric medications have been identified to date.
Robust safety monitoring will be essential as neuropsychiatric trials scale.
What It Will Take to Build the Evidence Base
To determine whether GLP-1 agonists can improve the trajectory of neuropsychiatric illness, the next phase of research must be intentional and multidisciplinary. Five priorities will be critical:
1. Indication-Specific Trial Designs19
Future studies should be structured to focus on psychiatric endpoints rather than metabolic proxies. Trials should evaluate changes in craving, compulsivity, mood, cognition, and antipsychotic-induced weight gain using validated psychiatric instruments and adequate powering.
2. Precision in Patient Selection3,10
GLP-1s may not benefit all neuropsychiatric populations. Hypothesis-driven subgroup studies are necessary to investigate differences based on metabolic profile, inflammatory status, psychiatric phenotype, and medication history.
3. Deeper Mechanistic Insight20,21
Further research should integrate neuroimaging, biomarker analyses, and translational neuroscience to clarify causal pathways involving neurotransmitters, neuroimmune signaling, and metabolic-brain communication.
4. Longitudinal Safety and Durability Data7,10
Given the chronic nature of many psychiatric disorders, long-term evaluation of metabolic status, psychiatric symptom trajectories, neurocognition, and treatment durability will be essential.
5. Neuropsychiatric Trials Should Reflect Real Life22
Psychiatric disorders and metabolic diseases disproportionately affect marginalized populations. Future GLP-1 neuropsychiatry trials should ensure representation across race, ethnicity, socioeconomic status, BMI ranges, comorbidity profiles, and geographic settings. Without deliberate inclusion, therapeutic advances risk reinforcing existing disparities.
A High-Potential Frontier for Neuropsychiatric Care
The convergence of neuroscience, psychiatry, and metabolic medicine has created one of the most promising new therapeutic frontiers. GLP-1 receptor agonists sit at the center of this intersection, supported by compelling evidence across depression, addiction, compulsive behaviors, and antipsychotic-related metabolic burden. The next step requires disciplined, purpose-built neuropsychiatric research.
From psychiatric trial leadership to operational execution across diverse and complex patient populations, the Alliance Clinical Network is positioned to support next-generation trials at this intersection of metabolic and neuropsychiatric innovation.
1 Centers for Disease Control and Prevention. (2024). National Health Interview Survey, 2019–2022: Trends in prescribed GLP-1 medications. CDC National Center for Health Statistics.
2 Samuel D. Emmerich, D.V.M., Cheryl D. et al. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023.
3 De Giorgi, R., Koychev, I., Adler, A, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine, Volume 74, 102726.
4 Klausen, M. K., Vestergaard, C. H., Faurholt-Jepsen, M., et al. (2022). Exenatide once weekly for alcohol use disorder: A randomized, placebo-controlled clinical trial. JCI Insight, 7(19), e159863.
5 Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013 Aug;38(8):1259-70.
6 Hendershot, C. S., Bremmer, M. P., Paladino, M. B., et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405.
7 De Giorgi, R., Millar, H., O’Brien, M., & Stubbs, B. (2025). An analysis on the role of glucagon-like peptide-1 receptor agonists in cocaine, antipsychotic- and olanzapine-induced weight gain and glucose intolerance. Nature Metabolism.
8 Aoun L, Almardini S, Saliba F, et al. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol. 2024 Feb 29;35:100333.
9 Arillotta, D., Floresta, G., Papanti Pelletier, G. D., Guirguis, et al. (2024). Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behaviour, and libido: Insights from social media using a mixed-methods approach. Brain Sciences, 14(6), 617.
10 Carmellini, P., Mandolini, G. M., & Pompili, M. (2025). GLP-1 receptor agonists in mood disorders: A psychiatric perspective. Life, 15(9), 1422.
11 Chen X, Zhao P, Wang W, et al. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry. 2024 Jan;32(1):117-127.
12 Jacobson S, Margolese N, Margolese HC. (2025). GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness. Can J Psychiatry.
13 Bak M, Campforts B,Domen P, et al. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis. Acta Psychiatr Scand. 2024;150(6):516‐529.
14 Teixeira, L. C. R., Luizon, M. R., & Gomes, K. B. (2025). Exploring the role of GLP-1 receptor agonists in Alzheimer’s disease: A review of preclinical and clinical evidence. Receptors, 4(1), 2.
15 Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013 Oct 14;7:181.
16 Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci. 2022 Sep 1;16:970925.
17 Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, Pothos EN, Kahn CR. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3463-8.
18 Pierret ACS, Mizuno Y, Saunders P, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(7):643–653.
19 Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405.
20 Zhu C, Li H, Kong X, Wang Y, Sun T, Wang F. Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Front Pharmacol. 2022 Mar 1;13:819470.
21 Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2021 Jan 18;14:614884.
22 Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, Pitman A, Soneson E, Steare T, Wright T, Griffiths SL. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024 Feb;23(1):58-90.
